Overview

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r DLBCL who received CD19 CAR-T therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Collaborator:
Shanghai Celluar Biopharmaceutical Group Ltd.